Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Breast cancer (all types), drawn from the whole corpus: 88 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Metastatic disease remains incurable for almost everyone.
Nothing recorded yet.
Also on OnCo: Atlas of advanced disease · How cancer spreads: the metastasis stages.
Triple-negative and inflammatory breast cancer still have the worst outlook.
Overdiagnosis from screening and overtreatment of low-risk DCIS.
Nothing recorded yet.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Survival gaps between countries and between Black and white women in the same country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 53 changes by month →When this page itself was last checked or edited.
Gedatolisib with fulvestrant, with or without palbociclib, HR+/HER2- advanced breast cancer (VIKTORIA-1)
Maintenance in HR+/HER2+ advanced breast cancer with anti-HER2 and endocrine therapy (PATINA)
FDA approves palbociclib with trastuzumab, with or without pertuzumab, and endocrine therapy for the maintenance treatment of HR-positive, HER2-positive metastatic breast cancer
Early-stage HER2+ breast cancer: neoadjuvant (DESTINY-Breast11) and post-neoadjuvant residual disease (DESTINY-Breast05)
HR+/HER2+ advanced breast cancer maintenance with anti-HER2 and endocrine therapy